WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6.
Ji J, Liu W, Xu Y, Xu Z, Lv M, Feng J, Lv J, He X, Zhang Z, Xie M, Jing A, Wang X, Ma J, Liu B.
Ji J, et al.
Front Pharmacol. 2023 Jan 19;13:1072194. doi: 10.3389/fphar.2022.1072194. eCollection 2022.
Front Pharmacol. 2023.
PMID: 36744210
Free PMC article.